Systematic identification of lincRNA-derived immunogenic peptides in melanoma [0.03%]
系统识别黑色素瘤中由长链非编码RNA衍生的免疫原性肽
Emilie Dupré,Amélie Guiho,Tiffany Beauvais et al.
Emilie Dupré et al.
The search for reliable shared tumor-specific antigens (TSAs) to improve cancer immunotherapy is on-going. The so-called non-coding regions of the genome have recently been shown to give rise to immunogenic peptides, including the melanoma-...
Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine [0.03%]
Dexmedetomidine的α2-肾上腺素受体激动剂的免疫抗肿瘤效应
Lucillia Bezu,Oliver Kepp,Guido Kroemer
Lucillia Bezu
The α2-adrenergic receptor agonist dexmedetomidine (DEX) exerts context-dependent antitumor effects, with its efficacy influenced by dose, immune cell involvement and combination with immune checkpoint inhibitors. It will be important to u...
Immune modulation following α and β- radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model [0.03%]
针对预临床肿瘤模型中靶向成纤维细胞活化蛋白-α的α和β放射性核素治疗后的免疫调节作用
Hannelore Ceuppens,Kirsten De Ridder,Thomas Ertveldt et al.
Hannelore Ceuppens et al.
α- and β--emitting radionuclides targeting human fibroblast activation protein-α (hFAP) are under investigation for cancer therapy. In prior work, analysis of the tumor microenvironment 24 h after therapy completion indicated therapy-ind...
Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response [0.03%]
患者衍生的卵巢癌模型展示了肿瘤相关巨噬细胞对治疗反应的影响
Parisa Nikeghbal,Danielle Burke,Dalet Armijo et al.
Parisa Nikeghbal et al.
While most ovarian cancer (OC) patients respond to front-line platinum/taxane chemotherapy and surgical debulking, the majority will develop platinum-resistance and recur. Our study investigated how tumor-associated macrophages (TAMs) withi...
Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration [0.03%]
FAK抑制通过介导CXCL10分泌增强CD8+T细胞浸润从而促进胰腺癌免疫治疗
Yu-Chen Shi,Qingling An,Na Tang et al.
Yu-Chen Shi et al.
Immunotherapy has demonstrated potential in treating various malignant tumors, but its efficacy in pancreatic cancer (PC) remains limited, possibly due to the dense stromal components and immunosuppressive microenvironment of PC. Focal adhe...
Characteristics and significance of γδ T cells in colorectal cancer [0.03%]
肠道放射防护及免疫反应的遗传宿主因素研究进展——从模式动物到人类
Henna Karjalainen,Jouni Härkönen,Päivi Sirniö et al.
Henna Karjalainen et al.
Gamma-delta T cells are a subset of T cells that have features of both innate and adaptive immunity. Their role in cancer remains controversial, since both anti- and protumor functions have been reported. We aimed to shed light on the disti...
Correction [0.03%]
改正错误
Published Erratum
Oncoimmunology. 2025 Dec;14(1):2538308. DOI:10.1080/2162402X.2025.2538308 2025
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53-/- murine model of sarcoma [0.03%]
人类STING激动剂E7766诱导免疫性肿瘤清除，与肿瘤固有的STING表达无关：在KRASG12D/+ Trp53-/-小鼠肉瘤模型中的作用研究
Karys M Hildebrand,Kurt N Hildebrand,Carolina Salazar Arcila et al.
Karys M Hildebrand et al.
Soft tissue sarcomas (STS) are aggressive high-fatality cancers that affect children and adults. Most STS subtypes harbor an immunosuppressive tumor microenvironment (TME) and respond poorly to immunotherapy. Therapies capable of dismantlin...
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies [0.03%]
CD200免疫检查点的表达与接受抗CD38单克隆抗体治疗的多发性骨髓瘤患者的预后不良相关
Djamila Chemlal,Camille Pochard,Valentin Jacquier et al.
Djamila Chemlal et al.
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prosp...
An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer [0.03%]
HR阳性乳腺癌对CDK4/6抑制剂耐药的一种免疫学机制
Claudia Galassi,Giulia Petroni,Simon R V Knott et al.
Claudia Galassi et al.
CDK4/6 inhibitors are central to the clinical management of HR+HER2- breast cancer. We have recently demonstrated that immunosuppressive, IL17-secreting γδ T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism upon...